Casdozokitug

DB17513InvestigationalProtein Based Therapies

Casdozokitug: Overview.

Mechanism
Curator reviewed
Also known as
immunoglobulin G1-kappa, anti-[IL27 (interleukin 27,IL27p28, IL27A)], Homo sapiens monoclonal antibody,gamma1 heavy chain Homo sapiens (1-456) [VH (Homo sapiens IGHV3-21*01 (95.9%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT [8.8.19] (26-33.51-58.97-115)) (1-126) · Immunoglobulin G1, anti-(human interleukin 27) (human monoclonal SRF388 γ1-chain), disulfide with human monoclonal SRF388 κ-chain, dimer
Code names
CHS-388 · SRF-388

Resolves to

Compound
UNIIAL6I5N2HTNCAS2643331-37-5
Targets
Q8NEV9IL27

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Casdozokitug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In